Lupin recalls more than 2.5M prescription eye drop bottles, citing possible contamination

Fierce Pharma· July 13, 2026

Lupin is recalling more than 2.5 million bottles of prescription eye drops due to potential contamination issues. The scale of the recall indicates a significant impact on the company's ophthalmic product distribution and availability. For the pharmaceutical sector, this event highlights the ongoing regulatory focus on manufacturing standards and product safety for sterile solutions.

Read the full story at Fierce Pharma

Summary generated by RabbitReport AI from public reporting. The full article and original reporting belong to Fierce Pharma.

More in Pharmaceutical

US appeals court revives Teva lawsuit over Lilly osteoporosis drug

A U.S. appeals court has revived a lawsuit filed by Teva Pharmaceuticals against Eli Lilly involving an osteoporosis drug. The ruling reverses a previous decision, allowing Teva to continue its legal challenge against its industry rival. This development is critical for the pharmaceutical sector as it impacts the competitive landscape for bone health treatments. The case highlights the ongoing legal friction between major drugmakers over patent rights and market access.

July 13, 2026

Senate Hearing Probes Foreign Control Of Drug Supply

The Senate Special Committee on Aging is convening a hearing to investigate foreign ownership and control within the United States pharmaceutical supply chain. This inquiry coincides with the implementation of significant tariffs on patented drug imports, signaling a transition from policy discussion to urgent regulatory compliance for the industry. The outcome of these proceedings could fundamentally alter how pharmaceutical companies manage international manufacturing and domestic distribution strategies.

July 13, 2026

Efforts to reform federal drug pricing program 340B continue with new report, proposed CMS rule

Ongoing efforts to reform the federal 340B drug pricing program have advanced with the release of a new report and a proposed rule from the Centers for Medicare & Medicaid Services (CMS). These initiatives aim to address long-standing concerns regarding the program's oversight and the distribution of pharmaceutical discounts to eligible healthcare providers. For the pharmaceutical industry, these regulatory shifts are critical as they may redefine compliance requirements and financial interactions between manufacturers and covered entities.

July 13, 2026

BioMarin Pharmaceutical (BMRN) Following Its VOXZOGO FDA Filing And The Case For Undervaluation

BioMarin Pharmaceutical has reached a significant regulatory milestone with the FDA's acceptance of a supplemental New Drug Application for its rare disease therapy, VOXZOGO. The agency has set a target action date for February 28, 2027, as the company seeks to expand the clinical utility and market reach of its key growth driver. This development is a pivotal moment for the pharmaceutical sector, as it underscores the commercial potential of specialized genetic treatments amid a period of stock price recovery for the company.

July 13, 2026